Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADVM 
Adverum Biotechnologies Inc (ADVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: ADVM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.75
1 Year Target Price $19.75
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 118.49% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 57.66M USD | Price to earnings Ratio - | 1Y Target Price 19.75 |
Price to earnings Ratio - | 1Y Target Price 19.75 | ||
Volume (30-day avg) 7 | Beta 0.7 | 52 Weeks Range 1.78 - 9.95 | Updated Date 07/17/2025 |
52 Weeks Range 1.78 - 9.95 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -15818.1% |
Management Effectiveness
Return on Assets (TTM) -48.76% | Return on Equity (TTM) -144.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 56276781 | Price to Sales(TTM) 57.66 |
Enterprise Value 56276781 | Price to Sales(TTM) 57.66 | ||
Enterprise Value to Revenue 65.04 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 20890700 | Shares Floating 12277484 |
Shares Outstanding 20890700 | Shares Floating 12277484 | ||
Percent Insiders 13.1 | Percent Institutions 79.47 |
Upturn AI SWOT
Adverum Biotechnologies Inc
Company Overview
History and Background
Adverum Biotechnologies, Inc. (formerly Avalanche Biotechnologies) was founded in 2006. It is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. The company has evolved through various development stages, focusing on adeno-associated virus (AAV)-based gene therapies.
Core Business Areas
- Gene Therapy for Ocular Diseases: Adverum focuses on developing gene therapies for prevalent eye diseases, primarily wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Leadership and Structure
Adverum's leadership team consists of experienced professionals in gene therapy and biopharmaceutical development. The organizational structure is typical of a biotech company, with departments for research, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Ixo-vec (ADVM-022): Ixo-vec (ADVM-022) is Adverum's lead product candidate, an investigational gene therapy for wet AMD. As an investigational product, it has no market share yet. Competitors in the wet AMD space include Regeneron (Eylea), Roche/Novartis (Lucentis), and biosimilars.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, with significant investment and increasing regulatory approvals. Ocular gene therapy is a specific niche showing promise due to the eye's accessibility and immune-privileged status.
Positioning
Adverum aims to be a leader in ocular gene therapy, focusing on single-administration treatments with long-term efficacy. Its competitive advantage lies in its proprietary AAV vector technology and clinical expertise.
Total Addressable Market (TAM)
The wet AMD market is estimated to be billions of dollars annually. Adverum aims to capture a significant portion of this TAM by offering a potentially more convenient and effective treatment option than existing therapies.
Upturn SWOT Analysis
Strengths
- Proprietary AAV vector technology
- Focus on a large unmet medical need (wet AMD)
- Potential for single-administration treatment
- Experienced leadership team
Weaknesses
- Clinical trial setbacks and safety concerns in the past
- Reliance on a single lead product candidate
- High cash burn rate
- Relatively small market capitalization
Opportunities
- Positive clinical trial results for Ixo-vec
- Partnerships with larger pharmaceutical companies
- Expansion into other ocular indications
- Advancements in gene therapy manufacturing
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies and emerging gene therapies
- Adverse safety events
- Funding challenges
Competitors and Market Share
Key Competitors
- REGN
- NVS
- RHHBY
Competitive Landscape
Adverum competes with established pharmaceutical companies like Regeneron and Novartis/Roche, as well as other gene therapy developers. Its success depends on demonstrating superior efficacy and safety compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D investment and clinical trial progress rather than revenue generation.
Future Projections: Future growth depends on the successful development and commercialization of Ixo-vec and other pipeline candidates. Analyst estimates vary based on clinical trial outcomes and market potential.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Ixo-vec and exploration of new AAV vector technologies.
Summary
Adverum Biotechnologies is a clinical-stage gene therapy company with a focus on ocular diseases, particularly wet AMD. The company's future hinges on the success of its lead product candidate, Ixo-vec. While promising, Adverum faces risks related to clinical trial outcomes, regulatory approval, and competition. Maintaining a strong cash position is crucial for continued development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information is based on publicly available data, which may be subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adverum Biotechnologies Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-07-31 | President, CEO & Director Dr. Laurent Fischer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://adverum.com |
Full time employees 155 | Website https://adverum.com | ||
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.